A Study to Evaluate the Efficacy and Safety of AD-224

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

Also called NCT06291207

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 254 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06291207
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06291207. Randomized; double masking; primary purpose treatment. Start 2024-04-15 (actual); primary completion 2025-04-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AD-224
Condition
Hypertension,Essential
Intervention (Drug)
AD-224A
Intervention (Drug)
AD-224B
Intervention (Drug)
AD-224C
Intervention (Drug)
Placebo of AD-224A
Intervention (Drug)
Placebo of AD-224B
Intervention (Drug)
Placebo of AD-224C
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct06291207
Content hash
2adb7d140fe998e0675f87141d7934724b483fb36fe561148efc57a166aa29b9